Kiniksa Pharmaceuticals International, plc reported second quarter 2026 financial results, posting net product revenue of $243.6 million, a 55% increase from the prior year period. The company raised its full-year 2026 ARCALYST net product revenue guidance to $980–$995 million, up from the previous range of $930–$945 million. Net income for the quarter was $25.4 million, compared to $17.8 million in the same period last year. The firm also announced that its pivotal Phase 3 trial for KPL-387, PASTORALE, has begun enrolling and dosing patients for recurrent pericarditis. Kiniksa operates in the biopharmaceutical industry, developing and commercializing novel therapies for cardiovascular and inflammatory diseases.